Skip to content
NewsBlazeAU – Lifestyle
Author:
Transgene S.A.
Transgene Provides Business and Financial Update for Q1 2026
April 29, 2026
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
April 13, 2026
Availability of Transgene’s 2025 Universal Registration Document (URD)
April 9, 2026
←
Previous Page
1
2